Comparative Effectiveness and Safety of Seizure Prophylaxis Among Adults After Acute Ischemic Stroke

被引:2
|
作者
Moura, Lidia M. V. R. [1 ,2 ,3 ]
Donahue, Maria A. A. [2 ]
Yan, Zhiyu [2 ]
Smith, Louisa H. H. [2 ,3 ,10 ]
Hsu, John [4 ,5 ,6 ]
Newhouse, Joseph P. P. [4 ,7 ,8 ,9 ]
Schwamm, Lee H. H.
Haneuse, Sebastien
Hernandez-Diaz, Sonia [10 ]
Blacker, Deborah [10 ,11 ,12 ]
机构
[1] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[3] Harvard Med Sch, Dept Neurol, Boston, MA USA
[4] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA
[5] Massachusetts Gen Hosp, Mongan Inst, Boston, MA 02114 USA
[6] Harvard Med Sch, Dept Med, Boston, MA USA
[7] Natl Bur Econ Res, Cambridge, MA USA
[8] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA
[9] Harvard Kennedy Sch, Cambridge, MA USA
[10] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[11] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA
[12] Harvard Med Sch, Dept Psychiat, Boston, MA USA
基金
美国国家卫生研究院;
关键词
anticonvulsants; ischemic stroke; neurology; seizures; INTRACEREBRAL HEMORRHAGE; PROBABILITY; UPDATE; GUIDELINES; MANAGEMENT; IMPACT; DRUGS; TRIAL; RISK;
D O I
10.1161/STROKEAHA.122.039946
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background:Older adults occasionally receive seizure prophylaxis in an acute ischemic stroke (AIS) setting, despite safety concerns. There are no trial data available about the net impact of early seizure prophylaxis on post-AIS survival. Methods:Using a stroke registry (American Heart Association's Get With The Guidelines) individually linked to electronic health records, we examined the effect of initiating seizure prophylaxis (ie, epilepsy-specific antiseizure drugs) within 7 days of an AIS admission versus not initiating in patients >= 65 years admitted for a new, nonsevere AIS (National Institutes of Health Stroke Severity score <= 20) between 2014 and 2021 with no recorded use of epilepsy-specific antiseizure drugs in the previous 3 months. We addressed confounding by using inverse-probability weights. We performed standardization accounting for pertinent clinical and health care factors (eg, National Institutes of Health Stroke Severity scale, prescription counts, seizure-like events). Results:The study sample included 151 patients who received antiseizure drugs and 3020 who did not. The crude 30-day mortality risks were 219 deaths per 1000 patients among epilepsy-specific antiseizure drugs initiators and 120 deaths per 1000 among noninitiators. After standardization, the estimated mortality was 251 (95% CI, 190-307) deaths per 1000 among initiators and 120 (95% CI, 86-144) deaths per 1000 among noninitiators, corresponding to a risk difference of 131 (95% CI, 65-200) excess deaths per 1000 patients. In the prespecified subgroup analyses, the risk difference was 52 (95% CI, 11-72) among patients with minor AIS and 138 (95% CI, 52-222) among moderate-to-severe AIS patients. Similarly, the risk differences were 86 (95% CI, 18-118) and 157 (95% CI, 57-219) among patients aged 65 to 74 years and >= 75 years, respectively. Conclusions:There was a higher risk of 30-day mortality associated with initiating versus not initiating seizure prophylaxis within 7 days post-AIS. This study does not support the role of seizure prophylaxis in reducing 30-day poststroke mortality.
引用
收藏
页码:527 / 536
页数:10
相关论文
共 50 条
  • [11] THE CORTICAL LOCALIZATION OF SEIZURE AFTER ISCHEMIC STROKE
    BLADIN, CF
    CHAUDHARI, P
    BLACK, S
    NORRIS, JW
    STROKE, 1995, 26 (01) : 159 - 159
  • [12] Application of Conditional Logistic Regression Method in a Prospective Effectiveness Comparative Study Among Patients with Acute Ischemic Stroke
    Cai, Jianxiong
    Zhao, Yuanqi
    Guo, Xianping
    Zhao, Min
    Lu, Yubo
    Zhao, Ruizhi
    Cai, YeFeng
    Wu, Darong
    2011 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE WORKSHOPS, 2011, : 858 - 861
  • [13] Recurrent symptomatic seizure in post-ischemic stroke prophylaxis patients
    Cuciureanu, D. I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 258 - 258
  • [14] Safety Study of Edaravone for the treatment of acute ischemic stroke among Filipinos
    Batino, Laurence Kristoffer J.
    Navarro, Jose C.
    CEREBROVASCULAR DISEASES, 2024, 53 : 186 - 186
  • [15] Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke
    Estella, Angel
    Perez Ruiz, Miriam
    Jose Serrano, Juan
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (09):
  • [16] Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke
    Rousseau, Justin F.
    Weber, Jeremy M.
    Alhanti, Brooke
    Saver, Jeffrey L.
    Messe, Steven R.
    Schwamm, Lee H.
    Fonarow, Gregg C.
    Sheth, Kevin N.
    Smith, Eric E.
    Mullen, Michael T.
    Silva, Gisele Sampaio
    Mac Grory, Brian
    Xian, Ying
    Warach, Steven J.
    JAMA NETWORK OPEN, 2025, 8 (03)
  • [17] Nonlinear relationship between triglycerides and cognitive function after acute ischemic stroke among older adults
    Cao, Simin
    Teng, Liting
    Gao, Maofeng
    Hu, Shoudi
    Xiao, Shiyan
    Chen, Chen
    He, Yu
    Cheng, Shouzhen
    Xie, Xiaohua
    HELIYON, 2024, 10 (06)
  • [18] Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke
    Hackett, C. T.
    Ramanathan, R. S.
    Malhotra, K.
    Quigley, M. R.
    Kelly, K. M.
    Tian, M.
    Protetch, J.
    Wong, C.
    Wright, D. G.
    Tayal, A. H.
    THROMBOSIS RESEARCH, 2015, 135 (02) : 249 - 254
  • [19] Safety of Thrombolytic Therapy for Acute Ischemic Stroke after Recent Transient Ischemic Attack
    McKinney, James S.
    Masjuan, Jaime
    Purroy, Francisco
    Calvet, David
    Ay, Hakan
    Cucchiara, Brett L.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2012, 21 (07): : 551 - 554
  • [20] Comparative effectiveness and safety of clopidogrel versus aspirin in patients with acute ischemic stroke: A nationwide population-based study
    Huang, Hsin-Yi
    Wang, Chi-Chuan
    Wu, Chung-Hsuen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 9 - 10